BCL11B-related disorder in two canadian children: Expanding the clinical phenotype.


Journal

European journal of medical genetics
ISSN: 1878-0849
Titre abrégé: Eur J Med Genet
Pays: Netherlands
ID NLM: 101247089

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 21 12 2019
revised: 06 05 2020
accepted: 07 07 2020
pubmed: 14 7 2020
medline: 30 3 2021
entrez: 14 7 2020
Statut: ppublish

Résumé

The product of the BCL11B (B-Cell Leukemia 11) gene is a bi-functional transcriptional regulator that can act as either a repressor or an activator. It plays an important role in the development of the nervous, immune, and cutaneous systems, and is also involved in dental and craniofacial development. BCL11B-Related Disorder (BCL11BRD) is a novel rare neurodevelopmental disorder associated with mutations in BCL11B. A total of 17 patients have been described in the literature thus far. The main symptoms of BCL11BRD include global developmental delay, speech impairment, dental anomalies, feeding difficulties, refractive errors, dysmorphic features, and immunological abnormalities. In this report, we describe two Canadian girls, with pathogenic de novo BCL11B variants, both diagnosed via exome sequencing. One of the patients had global developmental delay, dental anomalies, dysmorphic features, dyskinesia and hypotonia; the latter two symptoms have not been previously reported in patients with BCL11BRD. She also had dysgenesis of corpus callosum and dilatation of the frontal horns of lateral ventricles, a brain anomaly that has been previously reported in only one other patient. The second patient had developmental delay, dysmorphic features, spasticity in lower limbs and dental anomalies. Our report contributes to the knowledge of the BCL11BRD, expands the clinical phenotype, and can also aid with genetic counseling of newly identified patients.

Identifiants

pubmed: 32659295
pii: S1769-7212(19)30844-4
doi: 10.1016/j.ejmg.2020.104007
pii:
doi:

Substances chimiques

BCL11B protein, human 0
Repressor Proteins 0
Tumor Suppressor Proteins 0

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

104007

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Masson SAS. All rights reserved.

Auteurs

M Prasad (M)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada.

T B Balci (TB)

Schulich School of Medicine and Dentistry, Western University, Department of Pediatrics, Division of Medical Genetics, London Health Sciences Centre, London, Ontario, Canada; Children's Health Research Institute, London, Ontario, Canada.

C Prasad (C)

Schulich School of Medicine and Dentistry, Western University, Department of Pediatrics, Division of Medical Genetics, London Health Sciences Centre, London, Ontario, Canada; Children's Health Research Institute, London, Ontario, Canada.

J D Andrews (JD)

Lawson Health Research Institute, London Health Sciences Centre, London, Ontario, Canada.

R Lee (R)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Dentistry, London Health Sciences Centre, London, Ontario, Canada.

M T Jurkiewicz (MT)

Schulich School of Medicine and Dentistry, Western University, London, Ontario, Canada; Department of Medical Imaging, London Health Sciences Centre, London, Ontario, Canada.

M P Napier (MP)

Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, Ontario, Canada.

S Colaiacovo (S)

Medical Genetics Program of Southwestern Ontario, London Health Sciences Centre, London, Ontario, Canada.

M J Guillen Sacoto (MJ)

GeneDx, Gaithersburg, MD, USA.

N Karp (N)

Schulich School of Medicine and Dentistry, Western University, Department of Pediatrics, Division of Medical Genetics, London Health Sciences Centre, London, Ontario, Canada; Children's Health Research Institute, London, Ontario, Canada. Electronic address: natalya.karp@lhsc.on.ca.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH